X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (88) 88
epilepsy (82) 82
sv2a ligand (62) 62
levetiracetam (61) 61
humans (60) 60
sv2a (60) 60
brivaracetam (52) 52
clinical neurology (47) 47
pharmacology & pharmacy (46) 46
synaptic vesicle protein (45) 45
double-blind (43) 43
male (43) 43
animals (41) 41
seizures (39) 39
adjunctive brivaracetam (36) 36
anticonvulsants - therapeutic use (34) 34
partial-onset seizures (33) 33
dose-response relationship, drug (32) 32
anticonvulsants (31) 31
adverse event profile (30) 30
antiepileptic drugs (30) 30
female (28) 28
pyrrolidinones - therapeutic use (28) 28
pharmacokinetics (27) 27
adult (26) 26
cns pharmacodynamics (25) 25
epilepsy - drug therapy (25) 25
middle aged (25) 25
analysis (24) 24
neurosciences (23) 23
placebo-controlled trial (23) 23
piracetam - analogs & derivatives (22) 22
anticonvulsants - pharmacology (21) 21
membrane glycoproteins - metabolism (20) 20
nerve tissue proteins - metabolism (20) 20
treatment outcome (19) 19
antiepileptic drug levetiracetam (18) 18
phase-iii (18) 18
rats (18) 18
binding-site (17) 17
pyrrolidinones - pharmacokinetics (17) 17
pyrrolidinones - pharmacology (17) 17
seizures - drug therapy (17) 17
adolescent (16) 16
adults (16) 16
anticonvulsants - pharmacokinetics (16) 16
brain (16) 16
mice (16) 16
pyrrolidinones - administration & dosage (16) 16
young adult (16) 16
aged (15) 15
binding sites (15) 15
ligands (15) 15
neurology (15) 15
antiepileptic drug (14) 14
pyrrolidinones - adverse effects (14) 14
efficacy (13) 13
piracetam - pharmacology (13) 13
anticonvulsants - administration & dosage (12) 12
anticonvulsants - adverse effects (12) 12
binding (12) 12
etiracetam (12) 12
disease models, animal (11) 11
epilepsies, partial - drug therapy (11) 11
expression (11) 11
human brain (11) 11
protein binding (11) 11
safety (11) 11
antiepileptic agents (10) 10
double-blind method (10) 10
drug therapy (10) 10
focal epilepsy (10) 10
ligand (10) 10
proteins (10) 10
psychiatry (10) 10
status epilepticus (10) 10
tolerability (10) 10
care and treatment (9) 9
medicine & public health (9) 9
area under curve (8) 8
brain - drug effects (8) 8
drug therapy, combination (8) 8
neurons (8) 8
rats, sprague-dawley (8) 8
alzheimers-disease (7) 7
binding characteristics (7) 7
brain - metabolism (7) 7
clinical trials (7) 7
clinical trials as topic (7) 7
complications and side effects (7) 7
drug dosages (7) 7
drug interactions (7) 7
membrane glycoproteins - genetics (7) 7
nerve tissue proteins - genetics (7) 7
profile (7) 7
synaptotagmin (7) 7
animal models (6) 6
anticonvulsants - chemistry (6) 6
convulsions & seizures (6) 6
currents (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 12/2013, Volume 721, Issue 1-3, pp. 185 - 192
Levtiracetam (Lev), an inhibitor of SV2A (synaptic vesicle protein A2), affected the ATP-dependent priming of Ca -regulated exocytosis in antral mucous cells... 
Gastric mucin | ATP-dependent priming | SV2A | Ca2+-regulated exocytosis | Levetiracetam | regulated exocytosis | HUMAN BRAIN | SYNAPTOTAGMIN | BINDING CHARACTERISTICS | RELEASE | SYNAPTIC VESICLE PROTEIN-2 | CA2 | CALCIUM | PHARMACOLOGY & PHARMACY | SECRETION | MODULATION | ACTS
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 12/2008, Volume 601, Issue 1-3, pp. 99 - 102
Previous examinations demonstrated antidystonic effects of the synaptic vesicle protein 2A (SV2A) ligand levetiracetam in the dt mutant hamster, an animal... 
Antiepileptic drug | Therapeutic | Dystonic choreoathetosis | SV2A ligand | Movement disorder | Dyskinesia
Journal Article
Epilepsy Research, ISSN 0920-1211, 01/2019, Volume 149, pp. 88 - 91
Brivaracetam is available in intravenous formulation, and its favourable pharmacokinetic profile makes it a promising agent in the treatment of status... 
Therapeutic drug monitoring | Critical care | Outcome | Retrospective | SV2A LIGAND | REFRACTORY STATUS EPILEPTICUS | PROGNOSIS | CLINICAL NEUROLOGY | LACOSAMIDE
Journal Article
Journal of Cerebral Blood Flow & Metabolism, ISSN 0271-678X, 11/2018, Volume 38, Issue 11, pp. 2041 - 2052
Synaptic vesicle glycoprotein 2A (SV2A) is ubiquitously present in presynaptic terminals. Here we report kinetic modeling and test–retest reproducibility... 
neurodegeneration | Brain imaging | positron emission tomography | synapses/dendrites | kinetic modeling | PROTEIN 2A | HUMAN BRAIN | PET TRACER | RADIOTRACER | NEUROSCIENCES | SV2A | ENDOCRINOLOGY & METABOLISM | BINDING-SITE | LIGAND | HEMATOLOGY | EXPRESSION | LEVETIRACETAM | synapses | dendrites | Original
Journal Article
EUROPEAN JOURNAL OF PHARMACOLOGY, ISSN 0014-2999, 12/2008, Volume 601, Issue 1-3, pp. 99 - 102
Previous examinations demonstrated antidystonic effects of the synaptic vesicle protein 2A (SV2A) ligand levetiracetam in the dt(sz) mutant hamster, an animal... 
Antiepileptic drug | Therapeutic | CURRENTS | Dystonic choreoathetosis | GENERALIZED DYSTONIA | IDIOPATHIC DYSTONIA | INHIBITION | Movement disorder | DISEASE | ANIMAL-MODELS | BINDING-SITE | PHARMACOLOGY & PHARMACY | ANTAGONISTS | SV2A ligand | ANTIEPILEPTIC DRUG LEVETIRACETAM | Dyskinesia
Journal Article
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, ISSN 1433-7851, 09/2019, Volume 58, Issue 37, pp. 13149 - 13154
Despite a growing interest in CHF2 in medicinal chemistry, there is a lack of efficient methods for the insertion of (CHFF)-F-18 into druglike compounds.... 
REAGENT | SV2A LIGAND | ARENES | MOUSE | CHEMISTRY, MULTIDISCIPLINARY | C-H DIFLUOROMETHYLATION | IODIDES | HETEROARENES | C-H activation | TRACER | photochemistry | ARYL | radiochemistry | flow chemistry | fluorine | TRIFLUOROMETHYLATION
Journal Article